Patents Assigned to Array Biopharma Inc.
  • Patent number: 8044083
    Abstract: The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: October 25, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Robert Groneberg, Laurence E. Burgess, Darren Harvey, Ellen Laird, Mark C. Munson, James P. Rizzi, Martha Rodriguez, Charles Todd Eary, Daniel John Watson
  • Patent number: 8039637
    Abstract: Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-1 and their synthetic intermediates: wherein Z, X1, X2, X5, R2 and R10 are as defined herein. Compounds of Formula Ia-1 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: October 18, 2011
    Assignee: Array BioPharma Inc.
    Inventors: John DeMattei, Sagar Shakya, Anthony D. Piscopio, Bruno P. Hache, Matthew Charles Evans, James Gair Ford, Simon Mark Pointon, Koen Peeters, Timothy John Lilley, John Leonard
  • Patent number: 8039639
    Abstract: A compound of Formula II and salts thereof are useful in the preparation of a compound of Formula I and pharmaceutically acceptable salts and prodrugs thereof.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: October 18, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Robert Groneberg, Laurence E. Burges, Darren Harvey, Ellen Laird, Mark C. Munson, James P. Rizzi, Martha Rodriguez, Charles Todd Eary, Daniel John Watson
  • Publication number: 20110245230
    Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: June 14, 2011
    Publication date: October 6, 2011
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Banka, Jun Liang, Brian Safina, Jun Li, Christine Chabot
  • Patent number: 8026233
    Abstract: Compounds of formula (I): in which A, B, X, Ar1, R8 and R4 have any of the meanings given in the specification, are inhibitors of p38 useful in the treatment and prevention of various disorders mediated by p38.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: September 27, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Mark C. Munson, Kevin W. Hunt, Christopher T. Clark, Ganghyeok Kim, Laurence E. Burgess, James P. Rizzi
  • Patent number: 8022222
    Abstract: Provided are compounds of formula I wherein R2, L, Z, Y, G and R1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: September 20, 2011
    Assignee: Array Biopharma, Inc.
    Inventors: Thomas D. Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Rustam Ferdinand Garrey, Ronald Jay Hinklin, Ajay Singh, Timothy M. Turner
  • Patent number: 8022223
    Abstract: Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: September 20, 2011
    Assignee: Array Biopharma, Inc.
    Inventors: Thomas D. Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Ronald Jay Hinklin, Ajay Singh
  • Patent number: 8017641
    Abstract: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: September 13, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Mark Munson, David A. Mareska, Youngboo Kim, Robert D. Gronenberg, James P. Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey
  • Patent number: 8003651
    Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: August 23, 2011
    Assignees: Array BioPharma Inc., Genertech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Banka, Jun Liang, Brian Safina, Jun Li, Christine Chabot
  • Patent number: 8003662
    Abstract: Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: August 23, 2011
    Assignee: Array BioPharma, Inc.
    Inventors: James F. Blake, Steven Boyd, Jason De Meese, John J. Gaudino, Allison L. Marlow, Jeongbeob Seo, Allen A. Thomas, Hongqi Tian
  • Patent number: 8003805
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: August 23, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • Patent number: 7973170
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: July 5, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • Patent number: 7956073
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: June 7, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Joseph P. Lyssikatos, Thomas D. Aicher, Ellen R Laird, John Robinson, Shelley Allen
  • Publication number: 20110130406
    Abstract: Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: September 5, 2008
    Publication date: June 2, 2011
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Jason DeMeese, John Gaudino, Alicia Tarin Neitzel, Paul Lunghofer, Jeongbeob Seo, Hongqi Tian, Wendy B. Young, Daniel P. Sutherlin
  • Publication number: 20110118235
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Application
    Filed: August 18, 2010
    Publication date: May 19, 2011
    Applicants: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • Patent number: 7932277
    Abstract: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: April 26, 2011
    Assignees: InterMune, Inc., Array Biopharma Inc.
    Inventors: Scott Seiwert, Steven W. Andrews, Leonid Beigelman, Lawrence M. Blatt, Brad Buckman, Kevin R. Condroski, Yutong Jiang, Robert J. Kaus, April L. Kennedy, Timothy S. Kercher, Michael A. Lyon, Bin Wang
  • Publication number: 20110092479
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: February 27, 2009
    Publication date: April 21, 2011
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Kateri A. Ahrendt, Alexandre J. Buckmelter, Jason De Meese, Jonas Grina, Joshua D. Hansen, Ellen R. Laird, Paul Lunghofer, David Moreno, Brad Newhouse, Li Ren, Jeongbeob Seo, Hongqi Tian, Steven M. Wenglowsky, Bainian Feng, Janet Gunzner, Kim Malesky, Simon Mathieu, Joachim Rudolph, Zhaoyang Wen, Wendy B. Young
  • Publication number: 20110092485
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Application
    Filed: August 18, 2010
    Publication date: April 21, 2011
    Applicants: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong Woon Yang
  • Publication number: 20110065716
    Abstract: The present invention provides compounds, including pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: January 9, 2009
    Publication date: March 17, 2011
    Applicant: Array BioPharma Inc.
    Inventors: Josef R. Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mitchell, Keith Lee Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Steven Do, Jun Liang, Brian Safina, Birong Zhang
  • Patent number: 7893065
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, and W are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative and inflammatory diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: February 22, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake